Amneal Pharmaceuticals, Inc. (AMRX) AI Stock Analysis

Amneal Pharmaceuticals, Inc. is a developer, licensor, manufacturer, marketer, and distributor of generic and specialty pharmaceutical products worldwide. Headquartered in Bridgewater, New Jersey, the company operates across three segments: Generics, Specialty, and AvKARE. The Generics segment provides various formulations including oral solids, injectables, ophthalmics, and transdermals. The Specialty segment focuses on branded therapies for central nervous system disorders, endocrinology, and parasitic infections, featuring products such as Emverm, Rytary, and Unithroid. The AvKARE segment distributes pharmaceuticals, medical products, and services primarily to governmental agencies, including the Department of Defense and the Department of Veterans Affairs.

Annual revenue increased from $2.09B in FY2021 to $3.02B in FY2025, representing a 5-year compound annual growth rate of 8.7%. Operating performance transitioned from an operating margin of -4.3% in FY2022 to 14.0% in FY2025, alongside net income improving to $72.1M. Over the trailing twelve months, revenue reached $3.12B with an operating margin of 18.3% and a profit margin of 5.1%. For the latest quarter ended June 30, 2026, quarterly revenue expanded 9.9% year-over-year, while quarterly earnings grew 157.1% year-over-year, supported by trailing twelve month diluted earnings per share of $0.49.

As of June 30, 2026, Amneal held $127.6M in cash and short-term investments alongside total debt of $2.79B, resulting in net debt of $2.66B. Total assets stood at $3.78B against shareholders' equity of $33.0M, reflecting a debt-to-equity ratio of 84.54 and a current ratio of 2.20. In FY2025, the company produced $340.0M in operating cash flow and $269.9M in free cash flow, while spending $70.1M on capital expenditures. Over a 5-year span, the company's share count increased by 119.7%.

AMRX closed at $19.18 on October 16, 2026, reflecting a 1-year return of 94.3% compared to 16.8% for the S&P 500, and a 5-year return of 240.1% versus 83.0% for the index. The company trades at a trailing price-to-earnings ratio of 39.1x, above the median of its US-listed Healthcare peers at 24.6x. However, its forward price-to-earnings multiple of 6.3x and price-to-sales ratio of 2.1x sit below the peer group medians of 17.3x and 4.1x, respectively. The enterprise value of $9.40B represents an EV-to-EBITDA multiple of 15.1x against the peer median of 12.0x.

All 7 covering analysts maintain favorable views on AMRX, consisting of 4 Strong Buy and 3 Buy ratings. The mean price target of $22.71 sits 18.4% above the last close of $19.18. Consensus estimates project FY2026 revenue of $3.16B with EPS rising 23.4% to $1.02. For FY2027, 7 analysts project revenue of $3.44B and EPS of $1.19. The company has surpassed EPS estimates in each of the last 4 quarters, with the next earnings announcement scheduled for November 3, 2026.

This page is an AI-written research summary of Amneal Pharmaceuticals, Inc. (AMRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AMRX income statement, AMRX balance sheet, AMRX key metrics, AMRX analyst forecast, AMRX chart. See the AMRX stock overview for the latest quote and news.